GlaxoSmithKline logo

Our commitment to the developing world

Press release: 20 January 2010


20 January 2010: Andrew Witty, during a speech at the Council on Foreign Relations, announced an ‘open innovation’ strategy to help deliver new and better medicines for people living in the world’s poorest countries.

For more information, please read the press release, available in six languages:

Women and child

Transcript of speech to the Council on Foreign Relations


Referring to a speech given at the Council on Foreign Relations in New York on 20 January 2010, Mr Witty said,“We want to be a company that is truly a partner in addressing the healthcare challenges in the world's poorest countries, no matter how difficult they are. A restless company, never satisfied with what it has achieved, but always looking for ways of doing more."

Child with running water

Development of the candicate malaria vaccine


GSK has made a pledge to create a sustainable pricing model for the world’s most advanced malaria candidate vaccine.

Malaria-related press releases


Andrew Witty's Harvard speech: 13 February 2009


Andrew Witty in Africa

Multimedia


Map

B-roll


Images

First child to be vaccinated with malaria vaccine

First child receiving malaria vaccine

Mother setting up mosquito net

Malaria trial participants at the Kombewa District Hospital in Kisumu, Kenya

Malaria trial participants at the Kombewa District Hospital in Kisumu, Kenya

Malaria trial participants at the Kombewa District Hospital in Kisumu, Kenya

Links


 


Back to top

Research and development
Research & development
Find out more

About R&D at GSK